Psoriasis treated with ustekinumab in a patient with hepatitis C

International Journal of Dermatology

Volumn 52, Issue 3, 2013, Pages 381-382

  Abuchar, Adriana ^a   Vitiello, Magalys ^a   Kerdel, Francisco A ^a  

^a UNIVERSITY OF MIAMI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; STEROID; USTEKINUMAB;

ADULT; CASE REPORT; HEPATITIS C; HUMAN; LETTER; MALE; PANCREATITIS; PSORIASIS; PSORIATIC ARTHRITIS; ULTRAVIOLET B RADIATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, PSORIATIC; HEPATITIS C; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

EID: 84873959633     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.04876.x     Document Type: Letter

References (5)

1. Prignano F, Zanieri F, Milani S, Lotti T. Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report. Dermatol Ther 2009; 22: 386-390.
2. Richetta A, Maiani E, Carlomagno V, et al. Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab. Dermatol Ther 2009; 22: S16-S18.
3. Chien Al, Elder JT, Ellis CN. Ustekinumab: a new option in psoriasis therapy. Drugs 2009; 69: 1141-1152.
4. Kanazawa K, Aikawa T, Tsuda F, Okamoto H. Hepatitis C virus infection in patients with psoriasis. Arch Dermatol 1996; 132: 1391.
5. Paradisi A, Caldarola G, Capazzi R, et al. Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data. J Am Acad Dermatol 2010; 62: 1067-1069.